Gastrointestinal Cancer

Eric Van Cutsem, MD, PhD, discusses results from the phase IIIb CONSIGN study and the continuing advance of precision medicine in colorectal cancer.

James J. Lee, MD, PhD, discusses research into mismatch repair deficiency as a biomarker for PD-1 inhibition in colorectal cancer.

Yung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.

A collection of early phase clinical trials presented at the 2015 ASCO Annual Meeting demonstrated promising results for several novel agents in combination with established treatments for patients with hepatocellular carcinoma.

Michael P. Manns, MD, discusses the relationship between advances in hepatitis C care and the future of HCC treatment.

Guillem Argilés, MD, department of Medical Oncology, Vall d'Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.

All patients with colorectal cancer being considered for treatment with the EGFR inhibitors cetuximab and panitumumab should undergo extended RAS mutational testing to predict their response to the drugs.

Michael Manns, MD, the Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany, explains risk factors for hepatitis C-related hepatocellular carcinoma.

Patients with metastatic colorectal cancer benefited from treatment with cetuximab plus chemotherapy even after disease progression on a similar regimen as long as their tumors did not harbor mutations in any of four key genes.

Howard S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.

The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.

Findings from a large expanded access program have confirmed the efficacy and safety of regorafenib in patients with previously treated metastatic colorectal cancer.

TAS-102 demonstrated similar improvements in overall survival and progression-free survival in patients with heavily pretreated colorectal cancer from the phase III RECOURSE trial stratified by KRAS mutational status.

Adding an NK1 antagonist to a 5-HT3 receptor antagonist with dexamethasone improved antiemetic control for patients with colorectal cancer treated with an oxaliplatin-based regimen compared with the 5-HT3 antagonist and dexamethasone alone.

Andrew Zhu, MD, PhD, Associate Professor, Medicine, Harvard Medical School Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the REACH study, which looks at ramucirumab in advanced hepatocellular carcinoma.